Medicus Pharma Ltd (MDCX)

$0.26 +0.00 (1.27%)
Market Cap 16.43M
Revenue (ttm) 0.00
Net Income (ttm) -35.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -10.45
Volume 2,488,000
Avg Vol 1,742,698
Day's Range N/A - N/A
Shares Out 63.18M
Stochastic %K 17%
Beta 0.12
Analysts Strong Sell
Price Target $4.50

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus P...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 610 636 0184
Address:
300 Conshohocken State Road, Suite 200, West Conshohocken, United States
robertward
robertward Aug. 19 at 2:41 PM
$MDCX I did a little research into the company and decided to buy some shares, but I usually ask the bowls in that specific stock to provide a little bit of background or upcoming catalyst because I might not have captured everything in my initial research. Would anyone out there mind giving me a few of the big upcoming catalyst just so I can make sure I’ve done my due diligence. Appreciate any and all input.
0 · Reply
Sum_guy_69
Sum_guy_69 Aug. 19 at 12:54 PM
$MRNA $MDCX $OCGN 🥰
0 · Reply
Ewolf17
Ewolf17 Aug. 19 at 12:27 PM
$MDCX All the way .79 !! Let’s go
0 · Reply
Cullousus
Cullousus Aug. 18 at 5:56 PM
$MDCX it can easily jump in price its always been about specific pr thats needed. Till then may slide sideways.
0 · Reply
2TrustHim
2TrustHim Aug. 18 at 3:43 PM
$MDCX Is This Ever Going To See $.80 Again?
1 · Reply
Sum_guy_69
Sum_guy_69 Aug. 18 at 3:09 PM
$MDCX nice sale price 🤑
0 · Reply
Cullousus
Cullousus Aug. 17 at 8:12 PM
$MDCX
0 · Reply
Cullousus
Cullousus Aug. 17 at 2:41 PM
$MDCX one real good pr and Price will jump nicely.
0 · Reply
Cullousus
Cullousus Aug. 17 at 1:05 PM
$MDCX
0 · Reply
Cullousus
Cullousus Aug. 17 at 12:34 AM
$MDCX pretty consistent pattern here should see good rebound this week.
0 · Reply
Latest News on MDCX
Medicus Pharma price target lowered to 90c from $1 at Alliance Global

2026-08-17T12:55:34.000Z - 2 days ago

Medicus Pharma price target lowered to 90c from $1 at Alliance Global

Medicus Pharma reports Q2 EPS (21c) vs (43c) last year

2026-08-17T08:38:33.000Z - 2 days ago

Medicus Pharma reports Q2 EPS (21c) vs (43c) last year

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 12, 2026, 6:00 PM EDT - 6 days ago

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Aug 3, 2026, 7:30 AM EDT - 16 days ago

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Medicus Pharma Teverelix granted investigational new drug authorization in UAE

2026-07-31T11:37:05.000Z - 19 days ago

Medicus Pharma Teverelix granted investigational new drug authorization in UAE

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Jul 31, 2026, 7:30 AM EDT - 19 days ago

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Medicus Pharma initiated with a Buy at Alliance Global

2026-07-28T11:12:13.000Z - 22 days ago

Medicus Pharma initiated with a Buy at Alliance Global

Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study

2026-07-27T13:10:48.000Z - 23 days ago

Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Jul 27, 2026, 8:17 AM EDT - 23 days ago

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Medicus Pharma receives FDA feedback, IRB approval for Teverelix study

2026-07-16T11:40:11.000Z - 4 weeks ago

Medicus Pharma receives FDA feedback, IRB approval for Teverelix study

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Jul 16, 2026, 7:30 AM EDT - 4 weeks ago

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Jun 22, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA

2026-06-15T11:51:23.000Z - 2 months ago

Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Jun 15, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Jun 11, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

UAE

Medicus Pharma submits substantial modification application through EU CTIS

2026-06-08T11:37:41.000Z - 2 months ago

Medicus Pharma submits substantial modification application through EU CTIS

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Jun 8, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

2026-06-03T13:37:23.000Z - 2 months ago

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

Medicus Pharma Announces $22 Million Non-Dilutive Financing

May 28, 2026, 8:00 AM EDT - 2 months ago

Medicus Pharma Announces $22 Million Non-Dilutive Financing

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

2026-05-14T22:18:41.000Z - 3 months ago

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:30 PM EDT - 3 months ago

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

2026-05-07T03:48:38.000Z - 3 months ago

Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

May 6, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma meets with lawmakers to support SkinJect designations

2026-04-27T13:31:02.000Z - 4 months ago

Medicus Pharma meets with lawmakers to support SkinJect designations

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Apr 27, 2026, 7:30 AM EDT - 4 months ago

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma initiated with a Buy at Roth Capital

2026-04-21T11:53:55.000Z - 4 months ago

Medicus Pharma initiated with a Buy at Roth Capital

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

2026-04-17T11:35:50.000Z - 4 months ago

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Apr 17, 2026, 7:30 AM EDT - 4 months ago

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Apr 15, 2026, 7:30 AM EDT - 4 months ago

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Medicus Pharma enters media partnership with New to The Street

2026-04-07T14:23:02.000Z - 4 months ago

Medicus Pharma enters media partnership with New to The Street

Medicus Pharma submits clinical study design to FDA for Teverelix

2026-04-06T11:37:11.000Z - 4 months ago

Medicus Pharma submits clinical study design to FDA for Teverelix

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Apr 6, 2026, 7:30 AM EDT - 4 months ago

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Apr 1, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Medicus Pharma reports principal investigator validation of Phase 2 data

2026-03-30T13:38:08.000Z - 5 months ago

Medicus Pharma reports principal investigator validation of Phase 2 data

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Mar 30, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Mar 26, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

2026-03-18T11:52:25.000Z - 5 months ago

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Mar 18, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Medicus Pharma announces SkinJect Phase 2 KOL update

2026-03-16T11:50:31.000Z - 5 months ago

Medicus Pharma announces SkinJect Phase 2 KOL update

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Mar 16, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Mar 10, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

2026-03-09T11:40:33.000Z - 5 months ago

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Mar 9, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 5, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Medicus Pharma To Participate in the 38th Annual Roth Conference

Mar 3, 2026, 7:30 AM EST - 6 months ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

Medicus Pharma on Bloomberg World

Feb 12, 2026, 7:30 AM EST - 6 months ago

Medicus Pharma on Bloomberg World

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Feb 10, 2026, 7:30 AM EST - 6 months ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 23, 2026, 7:30 AM EST - 7 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 22, 2026, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Jan 20, 2026, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 12, 2026, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Jan 5, 2026, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 22, 2025, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 15, 2025, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 9 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Dec 1, 2025, 8:00 AM EST - 9 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 24, 2025, 8:00 AM EST - 9 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 17, 2025, 7:30 AM EST - 9 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 14, 2025, 5:00 PM EST - 9 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 13, 2025, 7:30 AM EST - 9 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 22, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 14, 2025, 8:07 AM EDT - 11 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 13, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Oct 7, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 29, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 9:26 AM EDT - 11 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

robertward
robertward Aug. 19 at 2:41 PM
$MDCX I did a little research into the company and decided to buy some shares, but I usually ask the bowls in that specific stock to provide a little bit of background or upcoming catalyst because I might not have captured everything in my initial research. Would anyone out there mind giving me a few of the big upcoming catalyst just so I can make sure I’ve done my due diligence. Appreciate any and all input.
0 · Reply
Sum_guy_69
Sum_guy_69 Aug. 19 at 12:54 PM
$MRNA $MDCX $OCGN 🥰
0 · Reply
Ewolf17
Ewolf17 Aug. 19 at 12:27 PM
$MDCX All the way .79 !! Let’s go
0 · Reply
Cullousus
Cullousus Aug. 18 at 5:56 PM
$MDCX it can easily jump in price its always been about specific pr thats needed. Till then may slide sideways.
0 · Reply
2TrustHim
2TrustHim Aug. 18 at 3:43 PM
$MDCX Is This Ever Going To See $.80 Again?
1 · Reply
Sum_guy_69
Sum_guy_69 Aug. 18 at 3:09 PM
$MDCX nice sale price 🤑
0 · Reply
Cullousus
Cullousus Aug. 17 at 8:12 PM
$MDCX
0 · Reply
Cullousus
Cullousus Aug. 17 at 2:41 PM
$MDCX one real good pr and Price will jump nicely.
0 · Reply
Cullousus
Cullousus Aug. 17 at 1:05 PM
$MDCX
0 · Reply
Cullousus
Cullousus Aug. 17 at 12:34 AM
$MDCX pretty consistent pattern here should see good rebound this week.
0 · Reply
Cullousus
Cullousus Aug. 14 at 10:06 PM
$MDCX thanks for the dip
2 · Reply
razorsedge4343
razorsedge4343 Aug. 14 at 9:52 PM
$MDCX
1 · Reply
Ewolf17
Ewolf17 Aug. 14 at 8:59 PM
$MDCX bouncing back !!
0 · Reply
realditzy
realditzy Aug. 14 at 8:46 PM
$MDCX I’m out smh chart looks like shit
0 · Reply
Reesifer
Reesifer Aug. 14 at 8:33 PM
$MDCX got more at .27
0 · Reply
Ewolf17
Ewolf17 Aug. 14 at 8:16 PM
$MDCX miss .21 loss compared to.16 except it
0 · Reply
realditzy
realditzy Aug. 14 at 8:03 PM
$MDCX what the actual fawk
0 · Reply
Reesifer
Reesifer Aug. 14 at 8:00 PM
$MDCX added .2812
0 · Reply
2TrustHim
2TrustHim Aug. 14 at 7:57 PM
$MDCX Is This The Beginning Or Death Spiral Ending?
0 · Reply
Ewolf17
Ewolf17 Aug. 14 at 7:55 PM
$MDCX What’s going down ?
0 · Reply
Amb8675309
Amb8675309 Aug. 14 at 7:41 PM
$MDCX
0 · Reply
Sum_guy_69
Sum_guy_69 Aug. 14 at 7:33 PM
$MDCX 😔
0 · Reply